- Policy
- Chong Kun Dang cuts price of its Lucen BS by half
- by Lee, Tak-Sun Jan 25, 2024 05:50am
- Chong Kun Dang is offering a bargain price for its biosimilar. The company has decided to cut the price of its 'Lucen BS', a biosimilar of the macular degeneration treatment Lucentis (ranibizumab, Novartis), by half from next month. As a result, the price difference between it and the original product, as well as it and Samsung Bioepis
- Company
- Boehringer Ingelheim Korea appoints Ana-Maria Boie as new GM
- by Son, Hyung-Min Jan 25, 2024 05:49am
- Boehringer Ingelheim Korea announced on the 24th that it had appointed Ana-Maria Boie as the General Manager and Head of Human Pharma. The new GM, Ana-Maria Boie, is a seasoned expert with 24 years of experience in the pharmaceutical industry, in various areas including management, marketing, sales, and ESG. Boie joined Boehringer Ingelhe
- Company
- Samsung Biologics tops 1 trillion won in profit
- by Chon, Seung-Hyun Jan 25, 2024 05:49am
- For the first time, Samsung Biologics has surpassed a yearly operating profit of 1 trillion won among pharmaceutical companies in Korea. Due to the continued growth of CDMO services for biopharmaceuticals, the company has accumulated quarter sales exceeding 1 trillion won in consecutive quarters. According to the Financial Supervisory
- Opinion
- [Reporter’s View] KRPIA's new BOD signifies fresh starts
- by Eo, Yun-Ho Jan 25, 2024 05:49am
- Following its fresh start with new staff members and a restructured board of directors, KRPIA is stabilizing its operations. Previously, Korean Research-based Pharmaceutical Industry Association (KRPIA) faced increasing concerns regarding its operations, primarily involving leadership vacancy. The decrease in the number of board members c
- Company
- Sales of Esomezol ·Noltec↑ Nexium↓ in the PPI market
- by Kim, Jin-Gu Jan 25, 2024 05:49am
- Sales of major proton pump inhibitor (PPI) class of antiulcer drugs showed mixed performance last year. ‘Nexium (esomeprazole)’ saw a 4% year-on-year decline in prescriptions, while ‘Lanston LFDT (lansoprazole)’ and ‘Pariet (rabeprazole)’ also saw a decline in prescriptions. Hanmi Pharmaceutical's ‘Esomezol (esomeprazole)’ and Ilyan
- InterView
- Patent outlook after Forxiga withdrawal in Korea
- by Kim, Jin-Gu Jan 24, 2024 12:37pm
- If ‘Forxiga (dapagliflozin)’, a SGLT-2 inhibitor class treatment for diabetes, is withdrawn from the Korean market, the question is whether companies can begin selling generics containing the same active ingredient for the treatment of heart failure. The answer to the question is that selling Forxiga generics for the purpose of treati
- Opinion
- [Reporter’s View] Supply disruptions disclosed in real-time
- by Lee, Hye-Kyung Jan 24, 2024 05:46am
- As of January 10, it became possible to view the list of medicines that are at risk of short shortages or interruptions in real time. The Ministry of Food and Drug Safety (MFDS) has improved the quarterly drug manufacture, import, and supply interruption information system on the Nedrug webpage to allow real-time updates. As a result, not
- Company
- Potential of AVEO Oncology acquired by LG Chem
- by Jan 24, 2024 05:46am
- LG Chem's subsidiary AVEO Oncology is showing results in intractable cancers. AVEO, which was acquired by LG Chem in 2022 for about KRW 750 billion, specializes in developing new anticancer drugs and has recorded annual sales of about KRW 200 billion. AVEO owns Fotivda (tivozanib), which has been approved in the U.S. for the treatment of Stage I
- Company
- ‘I believe in MSD Korea and the Korean government'
- by Eo, Yun-Ho Jan 24, 2024 05:46am
- Applying for reimbursement extensions to 13 indications at the same time is an unprecedented move. This move was made by MSD Korea for its immuno-oncology drug Keytruda (pembrolizumab), and the case has been marked as a ‘historical first’ ever since the introduction of the positive-listing system in Korea. Applying for the reimbursement
- Policy
- Handok-Sanofi launches hypertension combo drug Aprovasc
- by Lee, Tak-Sun Jan 24, 2024 05:45am
- Aprovasc, a hypertension combination drug co-developed by Handok and Sanofi Aventis Korea, will enter the market in earnest with reimbursement on the 1st of next month. The product is a combination drug of ARB-class irbesartan, which was developed by Sanofi, and CCB-class amlodipine besylate. This is the first irbesartan-amlodipine combin
